PLx Pharma (Dipexium Pharmaceuticals) Priced, Nasdaq: PLXP
Late-stage biotech developing a topical antibiotic for diabetic foot ulcer infections.
Industry: Health Care
First Day Return: +17.0%
Industry: Health Care
PLXP
Late-stage biotech developing a topical antibiotic for diabetic foot ulcer infections.
| IPO Data | |
|---|---|
| IPO File Date | 02/06/2014 |
| Offer Price | $12.00 |
| Price Range $12.00 - $14.00 | |
| Offer Shares (mm) | 2.8 |
| Deal Size ($mm) | $33 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 03/12/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $33 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | New York, NY, United States |
| Founded | 2010 |
| Employees at IPO | 7 |
| Website www.dipexiumpharmaceuticals.com | |
IPO News for PLx Pharma (Dipexium Pharmaceuticals)
PLx Pharma (Dipexium Pharmaceuticals) (PLXP) Performance
